An elderly resident - one of the three alzheimer sufferers of the establishment- sits as a carer prepares lunch in a house at L'Hay¨-les- Roses on the outskirts of Paris on February 17, 2022, which is run as an alternative to the traditional carehome model. (Photo by ALAIN JOCARD / AFP) (Photo by ALAIN JOCARD/AFP via Getty Images)

Two decades of Alzheimer’s research may be based on deliberate fraud that has cost millions of lives

The suspicion that something was more than a little wrong with the model that is getting almost all Alzheimer’s research funding ($1.6 billion in the last year alone) began with a fight over the drug Simufilam. The drug was being pushed into trials by its manufacturer, Cassava Sciences, but a group of scientists who reviewed the drug …

Two decades of Alzheimer’s research may be based on deliberate fraud that has cost millions of lives Read More »